CADL Slides As Candel Therapeutics Posts Wider Q2 Loss

Candel Therapeutics Inc. stocks have been trading down by -8.21 percent following bearish sentiment over its latest clinical trial outlook.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CADL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Market Insights For CADL Traders

Q2 net loss of $0.52 per share was far worse than the prior-year $0.09 loss and well below expectations for roughly a $0.21–$0.23 loss.
Operating expenses jumped to $26.7M with no revenue, signaling aggressive spending against an unchanged top line.
Cash balance of about $201.6M is guided to fund operations through Q1 2028, offering a sizable but finite runway.
An insider or large holder filed a Form 144 to sell restricted shares, adding potential supply pressure to CADL.

Weekly Update Sep 07 – Sep 11, 2026: On Saturday, September 12, 2026 Candel Therapeutics Inc. stock [NASDAQ: CADL] is trending down by -8.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Candel Therapeutics (CADL) is an early‑stage oncology biotech with no revenue and deeply negative profitability (ROE ~‑82%, ROA ~‑56%, ROIC worse than ‑60%), consistent with a binary R&D story rather than a fundamentals‑driven cash generator. Operating loss of ~$26.7M and net loss of ~$38.9M in Q2 underscore heavy R&D intensity. However, the balance sheet is strong: ~$201.6M cash, minimal near‑term liabilities, current ratio >16x, and modest leverage (debt/equity ~0.4x) support cash runway into 2028.

Technically, CADL has broken from a tight consolidation (~$12.6–12.7) into a clear short‑term downtrend, with successive lower highs and lows from $12.7 to $10.4 over the recent sessions. Five‑minute candles show persistent supply on intraday bounces and heavier volume on down moves, indicating distribution rather than profit‑taking. The actionable level is $10.00: below that, momentum shorts are favored; above $11.50 on convincing volume, a tactical relief‑rally long becomes viable with stops below $10.75.

More Breaking News

Fundamentally, the wider‑than‑expected loss and doubling of operating expenses versus last year have materially disappointed the market, while the Form 144 filing signals potential insider supply that can cap rallies. Relative to healthcare and biotech indices, CADL offers higher cash runway but worse earnings surprise and higher execution risk. Near‑term, expect underperformance. Key levels: support at $10.00, resistance at $12.00–12.50. Base‑case 6–12 month risk‑weighted range: $7–11, skewed lower unless clinical or partnership catalysts emerge.

Quick Financial Overview

Candel Therapeutics Inc. (CADL) is trading under clear fundamental pressure after the Q2 print showed a net loss of $0.52 per share. That is not just a miss versus the roughly $0.21–$0.23 expected loss, it is also a sharp deterioration from the $0.09 loss a year earlier. For short-term traders, this type of negative earnings surprise often acts as a headwind until the market can reprice the risk around cash burn and execution.

The income statement shows operating expenses at $26.7M for the quarter, with no revenue reported. Research and development and related research expense totaled about $19.8M, while selling, general, and administrative costs were roughly $6.9M. Operating income came in at about -$26.7M and net income at about -$38.9M, keeping all the key profitability ratios deep in negative territory. Returns on assets and equity are strongly negative, which is typical for a pre-revenue biotech, but it reinforces that the story is entirely about future clinical success rather than current earnings power.

On the balance sheet, Candel Therapeutics Inc. shows around $201.6M in cash and cash equivalents, against total assets of about $208.1M and total liabilities near $82.0M. Liquidity ratios are extremely high, with a current ratio around 16 and quick ratio near 15.9, signaling ample near-term capacity to fund operations. Management projects this cash can support the company through Q1 2028, which reduces immediate financing risk but does not remove the longer-term need for value-creating catalysts.

From a price-action angle, CADL has been sliding on the weekly chart. The stock dropped from roughly $12.7 down toward $10.4 over the recent weekly prints, showing a clear loss of momentum after the earnings miss. Intraday, a 5-minute candle in the $11.32–$11.41 range washed out to an intraday low near $9.86 before settling around $10.55, a wide range that signals heavy selling pressure and emotional trading. For short-term traders, that kind of intraday washout can sometimes mark temporary capitulation, but without a positive catalyst the path of least resistance often remains to the downside.

Conclusion

Candel Therapeutics Inc. now sits at a tricky spot for traders. The fundamentals show deep losses, with Q2 net income around -$38.9M and no revenue, but also a sizeable cash war chest of about $201.6M and a guided runway into Q1 2028. That combination means CADL does not face immediate survival risk, yet the market must digest a much worse-than-expected loss, sharply higher operating expenses, and no offsetting top-line growth.

On top of the earnings miss, the Form 144 filing by an insider or large holder adds a potential overhang for CADL. Intent to sell restricted or control stock does not guarantee heavy dumping, yet it tells traders that supply could increase into any strength. Technically, the recent slide from the low $12s toward $10, along with the intraday flush under $10, shows sellers in control and volatility rising.

For short-term traders, the setup around Candel Therapeutics Inc. is now mainly a risk-management exercise: respect the downtrend, track how price reacts near recent lows, and watch for any shift in volume that might signal accumulation rather than distribution. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. That mindset applies here: CADL is a trading vehicle where the tape and volume should guide decisions rather than hopes for a quick turnaround. This remains a catalyst-sensitive biotech with a long cash runway but no revenue, so sentiment can swing fast on any clinical update. As I tell my students, “You do not get paid for predicting the future; you get paid for managing risk when the market proves you right or wrong.”

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!